- Home
- CRSP vs ATGE Comparison
CRSP vs ATGE Comparison
Compare CRSP & ATGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- ATGE
- Stock Information
- Founded
- CRSP 2013
- ATGE 1987
- Country
- CRSP Switzerland
- ATGE United States
- Employees
- CRSP N/A
- ATGE N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- ATGE Other Consumer Services
- Sector
- CRSP Health Care
- ATGE Consumer Discretionary
- Exchange
- CRSP Nasdaq
- ATGE Nasdaq
- Market Cap
- CRSP 4.2B
- ATGE 4.4B
- IPO Year
- CRSP 2016
- ATGE 1991
- Fundamental
- Price
- CRSP $59.12
- ATGE $119.26
- Analyst Decision
- CRSP Buy
- ATGE Strong Buy
- Analyst Count
- CRSP 16
- ATGE 3
- Target Price
- CRSP $71.20
- ATGE $135.67
- AVG Volume (30 Days)
- CRSP 3.5M
- ATGE 461.3K
- Earning Date
- CRSP 08-04-2025
- ATGE 08-07-2025
- Dividend Yield
- CRSP N/A
- ATGE N/A
- EPS Growth
- CRSP N/A
- ATGE 129.73
- EPS
- CRSP N/A
- ATGE 6.03
- Revenue
- CRSP $37,675,000.00
- ATGE $1,741,091,000.00
- Revenue This Year
- CRSP $30.25
- ATGE $14.09
- Revenue Next Year
- CRSP $268.62
- ATGE $6.36
- P/E Ratio
- CRSP N/A
- ATGE $19.92
- Revenue Growth
- CRSP N/A
- ATGE 13.10
- 52 Week Low
- CRSP $30.04
- ATGE $66.90
- 52 Week High
- CRSP $63.68
- ATGE $140.12
- Technical
- Relative Strength Index (RSI)
- CRSP 83.65
- ATGE 42.52
- Support Level
- CRSP $50.26
- ATGE $118.54
- Resistance Level
- CRSP $53.08
- ATGE $123.85
- Average True Range (ATR)
- CRSP 2.78
- ATGE 4.31
- MACD
- CRSP 0.93
- ATGE -0.75
- Stochastic Oscillator
- CRSP 98.13
- ATGE 16.06
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.